Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope

Zheyu Li, Yoshihiro Oka, Akihiro Tsuboi, Fumihiro Fujiki, Yukie Harada, Hiroko Nakajima, Tomoki Masuda, Yoko Fukuda, Mai Kawakatsu, Soyoko Morimoto, Takamasa Katagiri, Naoya Tatsumi, Naoki Hosen, Toshiaki Shirakata, Sumiyuki Nishida, Yutaka Kawakami, Keiko Udaka, Ichiro Kawase, Yusuke Oji, Haruo Sugiyama

研究成果: Article

17 引用 (Scopus)

抄録

The Wilms' tumor gene WT1 is overexpressed in various kinds of hematopoietic malignancies as well as solid cancers, and this protein has been demonstrated to be an attractive target antigen for cancer immunotherapy. WT1-specific CTL epitopeswith a restriction of HLA-A*2402 or HLA-A*0201 have been already identified. In the present study it has been demonstrated that a 9-mer WT1-derived WT1187 peptide, which had already been shown to elicit a WT1-specific CTL response with a restriction of HLA-A*0201, can also elicit a CTL response with a restriction of HLA-A*0206. In all three different HLA-A*0206+ healthy donors examined, WT1187 peptide-specific CTL could be generated from peripheral blood mononuclear cells, and the CTL showed cytotoxic activity that depended on dual expression of WT1 and HLA-A*0206 molecules. The present study describes the first identification of a HLA-A*0206-restricted, WT1-specific CTL epitope. The present results should help to broaden the application of WT1 peptide-based immunotherapy fromonly HLA-A*0201- positive to HLA-A*0206-positive cancer patients as well.

元の言語English
ページ(範囲)551-558
ページ数8
ジャーナルMicrobiology and Immunology
52
発行部数11
DOI
出版物ステータスPublished - 2008 11

Fingerprint

HLA-A Antigens
Epitopes
Peptides
Proteins
Immunotherapy
Wilms' Tumor Genes
Neoplasms
Hematologic Neoplasms
Blood Cells
Tissue Donors
Antigens
HLA-A*02:01 antigen

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology

これを引用

Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope. / Li, Zheyu; Oka, Yoshihiro; Tsuboi, Akihiro; Fujiki, Fumihiro; Harada, Yukie; Nakajima, Hiroko; Masuda, Tomoki; Fukuda, Yoko; Kawakatsu, Mai; Morimoto, Soyoko; Katagiri, Takamasa; Tatsumi, Naoya; Hosen, Naoki; Shirakata, Toshiaki; Nishida, Sumiyuki; Kawakami, Yutaka; Udaka, Keiko; Kawase, Ichiro; Oji, Yusuke; Sugiyama, Haruo.

:: Microbiology and Immunology, 巻 52, 番号 11, 11.2008, p. 551-558.

研究成果: Article

Li, Z, Oka, Y, Tsuboi, A, Fujiki, F, Harada, Y, Nakajima, H, Masuda, T, Fukuda, Y, Kawakatsu, M, Morimoto, S, Katagiri, T, Tatsumi, N, Hosen, N, Shirakata, T, Nishida, S, Kawakami, Y, Udaka, K, Kawase, I, Oji, Y & Sugiyama, H 2008, 'Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope', Microbiology and Immunology, 巻. 52, 番号 11, pp. 551-558. https://doi.org/10.1111/j.1348-0421.2008.00069.x
Li, Zheyu ; Oka, Yoshihiro ; Tsuboi, Akihiro ; Fujiki, Fumihiro ; Harada, Yukie ; Nakajima, Hiroko ; Masuda, Tomoki ; Fukuda, Yoko ; Kawakatsu, Mai ; Morimoto, Soyoko ; Katagiri, Takamasa ; Tatsumi, Naoya ; Hosen, Naoki ; Shirakata, Toshiaki ; Nishida, Sumiyuki ; Kawakami, Yutaka ; Udaka, Keiko ; Kawase, Ichiro ; Oji, Yusuke ; Sugiyama, Haruo. / Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope. :: Microbiology and Immunology. 2008 ; 巻 52, 番号 11. pp. 551-558.
@article{f9d4d6b915ea4e60a30c4a2481e88831,
title = "Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope",
abstract = "The Wilms' tumor gene WT1 is overexpressed in various kinds of hematopoietic malignancies as well as solid cancers, and this protein has been demonstrated to be an attractive target antigen for cancer immunotherapy. WT1-specific CTL epitopeswith a restriction of HLA-A*2402 or HLA-A*0201 have been already identified. In the present study it has been demonstrated that a 9-mer WT1-derived WT1187 peptide, which had already been shown to elicit a WT1-specific CTL response with a restriction of HLA-A*0201, can also elicit a CTL response with a restriction of HLA-A*0206. In all three different HLA-A*0206+ healthy donors examined, WT1187 peptide-specific CTL could be generated from peripheral blood mononuclear cells, and the CTL showed cytotoxic activity that depended on dual expression of WT1 and HLA-A*0206 molecules. The present study describes the first identification of a HLA-A*0206-restricted, WT1-specific CTL epitope. The present results should help to broaden the application of WT1 peptide-based immunotherapy fromonly HLA-A*0201- positive to HLA-A*0206-positive cancer patients as well.",
keywords = "Cancer, HLA-A*0206, Vaccine, WT1",
author = "Zheyu Li and Yoshihiro Oka and Akihiro Tsuboi and Fumihiro Fujiki and Yukie Harada and Hiroko Nakajima and Tomoki Masuda and Yoko Fukuda and Mai Kawakatsu and Soyoko Morimoto and Takamasa Katagiri and Naoya Tatsumi and Naoki Hosen and Toshiaki Shirakata and Sumiyuki Nishida and Yutaka Kawakami and Keiko Udaka and Ichiro Kawase and Yusuke Oji and Haruo Sugiyama",
year = "2008",
month = "11",
doi = "10.1111/j.1348-0421.2008.00069.x",
language = "English",
volume = "52",
pages = "551--558",
journal = "Microbiology and Immunology",
issn = "0385-5600",
publisher = "Center for Academic Publications Japan",
number = "11",

}

TY - JOUR

T1 - Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope

AU - Li, Zheyu

AU - Oka, Yoshihiro

AU - Tsuboi, Akihiro

AU - Fujiki, Fumihiro

AU - Harada, Yukie

AU - Nakajima, Hiroko

AU - Masuda, Tomoki

AU - Fukuda, Yoko

AU - Kawakatsu, Mai

AU - Morimoto, Soyoko

AU - Katagiri, Takamasa

AU - Tatsumi, Naoya

AU - Hosen, Naoki

AU - Shirakata, Toshiaki

AU - Nishida, Sumiyuki

AU - Kawakami, Yutaka

AU - Udaka, Keiko

AU - Kawase, Ichiro

AU - Oji, Yusuke

AU - Sugiyama, Haruo

PY - 2008/11

Y1 - 2008/11

N2 - The Wilms' tumor gene WT1 is overexpressed in various kinds of hematopoietic malignancies as well as solid cancers, and this protein has been demonstrated to be an attractive target antigen for cancer immunotherapy. WT1-specific CTL epitopeswith a restriction of HLA-A*2402 or HLA-A*0201 have been already identified. In the present study it has been demonstrated that a 9-mer WT1-derived WT1187 peptide, which had already been shown to elicit a WT1-specific CTL response with a restriction of HLA-A*0201, can also elicit a CTL response with a restriction of HLA-A*0206. In all three different HLA-A*0206+ healthy donors examined, WT1187 peptide-specific CTL could be generated from peripheral blood mononuclear cells, and the CTL showed cytotoxic activity that depended on dual expression of WT1 and HLA-A*0206 molecules. The present study describes the first identification of a HLA-A*0206-restricted, WT1-specific CTL epitope. The present results should help to broaden the application of WT1 peptide-based immunotherapy fromonly HLA-A*0201- positive to HLA-A*0206-positive cancer patients as well.

AB - The Wilms' tumor gene WT1 is overexpressed in various kinds of hematopoietic malignancies as well as solid cancers, and this protein has been demonstrated to be an attractive target antigen for cancer immunotherapy. WT1-specific CTL epitopeswith a restriction of HLA-A*2402 or HLA-A*0201 have been already identified. In the present study it has been demonstrated that a 9-mer WT1-derived WT1187 peptide, which had already been shown to elicit a WT1-specific CTL response with a restriction of HLA-A*0201, can also elicit a CTL response with a restriction of HLA-A*0206. In all three different HLA-A*0206+ healthy donors examined, WT1187 peptide-specific CTL could be generated from peripheral blood mononuclear cells, and the CTL showed cytotoxic activity that depended on dual expression of WT1 and HLA-A*0206 molecules. The present study describes the first identification of a HLA-A*0206-restricted, WT1-specific CTL epitope. The present results should help to broaden the application of WT1 peptide-based immunotherapy fromonly HLA-A*0201- positive to HLA-A*0206-positive cancer patients as well.

KW - Cancer

KW - HLA-A0206

KW - Vaccine

KW - WT1

UR - http://www.scopus.com/inward/record.url?scp=58249088449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249088449&partnerID=8YFLogxK

U2 - 10.1111/j.1348-0421.2008.00069.x

DO - 10.1111/j.1348-0421.2008.00069.x

M3 - Article

C2 - 19090835

AN - SCOPUS:58249088449

VL - 52

SP - 551

EP - 558

JO - Microbiology and Immunology

JF - Microbiology and Immunology

SN - 0385-5600

IS - 11

ER -